Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Net Income towards Common Stockholders (2021 - 2025)

Prime Medicine (PRME) has disclosed Net Income towards Common Stockholders for 5 consecutive years, with -$46.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 9.0% year-over-year to -$46.1 million, compared with a TTM value of -$201.1 million through Dec 2025, down 2.69%, and an annual FY2025 reading of -$201.1 million, down 2.69% over the prior year.
  • Net Income towards Common Stockholders was -$46.1 million for Q4 2025 at Prime Medicine, up from -$50.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$22.8 million in Q3 2021 and bottomed at -$65.6 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$45.7 million, with a median of -$45.9 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 61.69% in 2023, then surged 35.6% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$62.9 million in 2021, then soared by 35.45% to -$40.6 million in 2022, then plummeted by 61.69% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then dropped by 9.0% to -$46.1 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for PRME at -$46.1 million in Q4 2025, -$50.6 million in Q3 2025, and -$52.6 million in Q2 2025.